Dr. Schadendorf Discusses Sequencing Agents in Melanoma

Dirk Schadendorf, MD
Published: Wednesday, Dec 20, 2017



Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.
SELECTED
LANGUAGE


Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x